<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/212FBA96-7037-4D15-818A-22ECC6A7E6A8"><gtr:id>212FBA96-7037-4D15-818A-22ECC6A7E6A8</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:surname>Lingford-Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F0A3F403-8578-47AC-A520-9E6B1EDFC18F"><gtr:id>F0A3F403-8578-47AC-A520-9E6B1EDFC18F</gtr:id><gtr:firstName>Bill</gtr:firstName><gtr:surname>Deakin</gtr:surname><gtr:orcidId>0000-0002-2750-962X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/06EE5A67-AAAF-4775-ABC4-A83EECD2DF5B"><gtr:id>06EE5A67-AAAF-4775-ABC4-A83EECD2DF5B</gtr:id><gtr:firstName>Rebecca</gtr:firstName><gtr:surname>Elliott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5311E2FF-E2A6-419E-BA93-29A82BC923A8"><gtr:id>5311E2FF-E2A6-419E-BA93-29A82BC923A8</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:otherNames>D</gtr:otherNames><gtr:surname>Ersche</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A1E9B71F-1AD5-44B4-BAE5-6B51536B56AF"><gtr:id>A1E9B71F-1AD5-44B4-BAE5-6B51536B56AF</gtr:id><gtr:firstName>Edward</gtr:firstName><gtr:surname>Bullmore</gtr:surname><gtr:orcidId>0000-0002-8955-8283</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB718CC2-60A9-424C-874E-006BC98FFF1E"><gtr:id>FB718CC2-60A9-424C-874E-006BC98FFF1E</gtr:id><gtr:firstName>Jeffrey</gtr:firstName><gtr:otherNames>Wayne</gtr:otherNames><gtr:surname>Dalley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C67373B7-D390-4D49-BD31-1280BA65D1F5"><gtr:id>C67373B7-D390-4D49-BD31-1280BA65D1F5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Nutt</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B73D3567-D3B9-4FB7-9D67-C11475FC6E7F"><gtr:id>B73D3567-D3B9-4FB7-9D67-C11475FC6E7F</gtr:id><gtr:firstName>Eugenii</gtr:firstName><gtr:otherNames>Alfredovich</gtr:otherNames><gtr:surname>Rabiner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4E80443A-E7AA-4216-9492-FC8B1A583B53"><gtr:id>4E80443A-E7AA-4216-9492-FC8B1A583B53</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Robbins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3C32520F-0DF5-47AA-A2E4-BE9456F6CCC0"><gtr:id>3C32520F-0DF5-47AA-A2E4-BE9456F6CCC0</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>D</gtr:otherNames><gtr:surname>Beaver</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB544473-6BB4-495F-B7D1-D404EE8C059C"><gtr:id>FB544473-6BB4-495F-B7D1-D404EE8C059C</gtr:id><gtr:firstName>Laurence</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Reed</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5638B83E-8513-4CEC-A4BD-0C0805F4A22C"><gtr:id>5638B83E-8513-4CEC-A4BD-0C0805F4A22C</gtr:id><gtr:firstName>Franklin</gtr:firstName><gtr:otherNames>Imo</gtr:otherNames><gtr:surname>Aigbirhio</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4E48C463-C4A9-4E59-9610-26BF3B635A7D"><gtr:id>4E48C463-C4A9-4E59-9610-26BF3B635A7D</gtr:id><gtr:firstName>Barry</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Everitt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000018"><gtr:id>B38DF1F5-1462-4B52-B248-C9CB26A9705D</gtr:id><gtr:title>New drugs for addiction: focus on attenuating core behavioural components of heroin, cocaine and alcohol addiction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000018</gtr:grantReference><gtr:abstractText>Addiction to drugs such as heroin, cocaine and alcohol are a major problem in our society and globally. Is it possible to understand the processes that lead to addiction and to develop drugs that can be used for treatment? These are the two major questions that motivate the ICCAM addictions research cluster and this application. The ICCAM cluster brings together clinical and preclinical researchers from Imperial College London, Cambridge and Manchester Universities to address the problem of drug development for addiction. We seek to identify rational potential targets for drug development based upon our understanding of the pharmacology and brain processes engaged in addiction, rather than a random ?shotgun? approach. As a society, many think of addiction to drugs such as heroin, cocaine and alcohol as individual conditions with underlying social causes. This may not be the case with the established clinical condition, and this point of view may have impeded rational drug development for these disorders. The ICCAM cluster has identified multiple potential therapeutic drugs that may be of use in the treatment of addiction and now seeks to develop a ?platform? to rapidly assess their efficacy in humans. The word ?platform? means that we will adopt a common research approach based at each of our three sites to study the effects of particular drugs in human participants on processes that are relevant to addiction. We will use state of the art brain imaging techniques to study the effect of drugs on brain activity while a person responds to rewards, for example. These will be combined with neuropsychological assessment and monitoring of clinical outcomes to develop our research capacity.</gtr:abstractText><gtr:technicalSummary>Substance Use Disorders are of large and growing prevalence and carry substantial morbidity, mortality and public costs, yet pharmacotherapy is at an early stage of development. While social context, public health policy and psychological approaches are clearly relevant to development and treatment of addiction they are of both limited efficacy and specificity, underlining the need for pharmacotherapy. Despite the proven utility of some drug interventions for addiction [eg methadone, buprenorphine, naltrexone for heroin dependence and acamprosate and naltrexone for alcohol dependence] many patients do not respond. There are no proven pharmacotherapies for cocaine. There is a pressing need to develop novel pharmacotherapies acting across a broader range of components of addictive processes. To this end, there have been major advances in recent years in the understanding of the neurobiology of addiction which offers a new approach to identifying drug targets based on brain mechanisms. Our cluster will use a new experimental medicine research ?platform? and work with new potential drug treatments provided in part by our industrial stakeholder GlaxoSmithKline [GSK]. This initial cluster application develops a platform to assess candidate brain systems underpinning relapse at molecular, network and behavioural levels by assessing three high-likelihood, theoretically critical, target mechanisms comprising: dopamine DRD3 receptors, for relapse prevention primarily by reducing cue-reactivity/craving and impulsivity; ?-opioid receptors, which mediate the reinforcing effects of opioids and are also implicated in impulsivity and hence relapse, especially under conditions of stress; and NK1 receptors, implicated in both stress and reward responses. These drugs will be assessed with novel psychological and fMRI paradigms in human alcohol, heroin and cocaine addicts and in parallel preclinical studies. The platform will then be available for the study of other candidate treatment approaches for addiction that may include for example orexin antagonists and appetite regulating peptides.</gtr:technicalSummary><gtr:fund><gtr:end>2015-04-02</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1615226</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>link with GSK</gtr:description><gtr:id>68B90A9D-7959-4243-BC87-60B9CA907144</gtr:id><gtr:impact>several abstract presentations at intrnational PET meetings</gtr:impact><gtr:outcomeId>UMHyNaLNCnr-1</gtr:outcomeId><gtr:partnerContribution>help in data acquisition and analysis</gtr:partnerContribution><gtr:piContribution>this is a shared project with the PET analaysi team at GSK Uk in the clinical imaging centre</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Disseminating information about the MARC scheme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>22C94969-1D3E-4AC4-9DCE-25DDB8F84A12</gtr:id><gtr:impact>Presented MARC scheme, its aims and opportunities. Presented at RCPsych Addictions Faculty Meeting 2016 as well as other regional meetings alongside presentation of research outputs from other grants</gtr:impact><gtr:outcomeId>58c113634c56d7.46017246</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.imperial.ac.uk/medicine/mrc-addiction-research-clinical-training/</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>528093</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heptares Therapeutics Ltd</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>P1vital Consortium</gtr:fundingOrg><gtr:id>296D9A6A-ED12-4FF5-B1FC-C5BA26BB5C36</gtr:id><gtr:outcomeId>58c46e4a8c9445.46341390</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>413162</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ICCAM cluster (Cambridge site)</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DB086DC9-E07A-403C-BDC8-032E330CA53E</gtr:id><gtr:outcomeId>RC88HPKgZVm0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>3 fmri exposure paradigms to probe stress impulsivity and rewards sensitivity developed and validated</gtr:description><gtr:id>FA04D989-8AEF-49B4-BA7E-61BE835F5FCA</gtr:id><gtr:impact>useful platform technology</gtr:impact><gtr:outcomeId>GVS7bmTZ7Eu</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>addiction brain provocation tests</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>11F95890-3C3D-449D-BEA7-D1BEDFD3CF7D</gtr:id><gtr:title>Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8ae080c4928f8727a04fef8ca11181c"><gtr:id>e8ae080c4928f8727a04fef8ca11181c</gtr:id><gtr:otherNames>Taylor EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>585d52a1c9ac13.71491480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65ED866F-B98D-491F-B7CB-7C5E5860B123</gtr:id><gtr:title>The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05a41d1a38e9b91d9c07a1538f4b79ea"><gtr:id>05a41d1a38e9b91d9c07a1538f4b79ea</gtr:id><gtr:otherNames>McGonigle J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>58bf175d62df12.98145335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECE82E3B-0B86-4BEF-916D-6569C8833B4B</gtr:id><gtr:title>The neurobiology of addiction: the perspective from magnetic resonance imaging present and future.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16cffcecd972093820592ceb267d73bd"><gtr:id>16cffcecd972093820592ceb267d73bd</gtr:id><gtr:otherNames>Suckling J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>5a35e1fef17b04.78090372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3D1147E-697E-4C4A-8FEC-89FDF090842D</gtr:id><gtr:title>Endocannabinoids and striatal function: implications for addiction-related behaviours.</gtr:title><gtr:parentPublicationTitle>Behavioural pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d44910192c587842718b955f8a092ca4"><gtr:id>d44910192c587842718b955f8a092ca4</gtr:id><gtr:otherNames>Moreira FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0955-8810</gtr:issn><gtr:outcomeId>doi_55f9859855a04cce</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93F4604A-9E65-4732-A775-F3CA4743A40C</gtr:id><gtr:title>Baseline-dependent effects of cocaine pre-exposure on impulsivity and D2/3 receptor availability in the rat striatum: possible relevance to the attention-deficit hyperactivity syndrome.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a204b8a3d47fba451af19560ec2abf6"><gtr:id>1a204b8a3d47fba451af19560ec2abf6</gtr:id><gtr:otherNames>Caprioli D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>doi_55f9859855952ef6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A5690F3-A2F0-4C1A-8863-099C0D78D5D6</gtr:id><gtr:title>The role of the opioid system in alcohol dependence.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13654_24_24048097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BF725D4-4A81-42D3-B662-AB2983FE73BA</gtr:id><gtr:title>Progress in mind: focus on alcohol use disorders, an elsevier resource centre.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>56bb024ba8e915.02109578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4D3C825-96E5-4B5F-A504-12016C13B1CA</gtr:id><gtr:title>Estimating the harms of nicotine-containing products using the MCDA approach.</gtr:title><gtr:parentPublicationTitle>European addiction research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1022-6877</gtr:issn><gtr:outcomeId>56bb024c4ae787.90364526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F096A052-C9FF-44D3-95F1-A302DE78E38E</gtr:id><gtr:title>Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27fcd60488447ec2442bd8cacdc63faa"><gtr:id>27fcd60488447ec2442bd8cacdc63faa</gtr:id><gtr:otherNames>Murphy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>58bf1703cfb474.03308580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29A7E2B3-1997-475A-97E2-77E6346AAD38</gtr:id><gtr:title>Opioids and anxiety.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a5b38b282b1.10752523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C738C61-E9C0-4F71-AF3C-863BB8288241</gtr:id><gtr:title>Dissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a204b8a3d47fba451af19560ec2abf6"><gtr:id>1a204b8a3d47fba451af19560ec2abf6</gtr:id><gtr:otherNames>Caprioli D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>doi_55f9859855b7143f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2289BC0-734B-4C52-8C64-C3629C42A6D9</gtr:id><gtr:title>Brain ?-aminobutyric acid: a neglected role in impulsivity.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84940c7edb7b1b867f4fa9d1f2571c32"><gtr:id>84940c7edb7b1b867f4fa9d1f2571c32</gtr:id><gtr:otherNames>Hayes DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>doi_55f9859855acb19d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0CBF740-D998-44E3-BB64-2FE58D2526BD</gtr:id><gtr:title>Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.</gtr:title><gtr:parentPublicationTitle>European addiction research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09d883d26f08f9fc31846dad9ae0cd53"><gtr:id>09d883d26f08f9fc31846dad9ae0cd53</gtr:id><gtr:otherNames>Aubin HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1022-6877</gtr:issn><gtr:outcomeId>5675e1a805c05</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEA1346C-5473-4A1A-8FA5-953D4A5C6247</gtr:id><gtr:title>Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7fbfd746b88a4abbd78bc8abc6472d0"><gtr:id>a7fbfd746b88a4abbd78bc8abc6472d0</gtr:id><gtr:otherNames>Savulich G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>58bf1b45bea566.96665016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE91B51E-7F40-42D9-9877-5EB390D1A9C3</gtr:id><gtr:title>Increased impulsivity retards the transition to dorsolateral striatal dopamine control of cocaine seeking.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6892d496fb7cfc02f1e5c03661cddd5"><gtr:id>e6892d496fb7cfc02f1e5c03661cddd5</gtr:id><gtr:otherNames>Murray JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_540e170e170c8ef7a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>929DCC05-D204-43FC-BD21-B1D51F1C81FF</gtr:id><gtr:title>Synthesis and evaluation of 18F-FE-PEO in rodents: an 18F-labeled full agonist for opioid receptor imaging.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f97b77c7d2fd486349ce8c01bd73e8b"><gtr:id>9f97b77c7d2fd486349ce8c01bd73e8b</gtr:id><gtr:otherNames>Riss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>pm_13654_24_23297076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D693020-6EB1-4736-AA77-6BBB04257385</gtr:id><gtr:title>Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task.</gtr:title><gtr:parentPublicationTitle>Addiction biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4631014991d466f63409d5c5dbe88b79"><gtr:id>4631014991d466f63409d5c5dbe88b79</gtr:id><gtr:otherNames>Nestor LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1355-6215</gtr:issn><gtr:outcomeId>58bf16e0754c80.67616704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECC1B391-AC83-46E6-8254-676223827542</gtr:id><gtr:title>Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals.</gtr:title><gtr:parentPublicationTitle>Addiction biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e113e52d43c4a890bf4f81aa271f22de"><gtr:id>e113e52d43c4a890bf4f81aa271f22de</gtr:id><gtr:otherNames>Morris LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1355-6215</gtr:issn><gtr:outcomeId>58bf17378e2c02.47498743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BE00213-9C1C-4EAF-97B4-261F38039AF2</gtr:id><gtr:title>Anne Lingford-Hughes: to get into addiction, just say yes.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25717321b2b67901393ba7e142718aba"><gtr:id>25717321b2b67901393ba7e142718aba</gtr:id><gtr:otherNames>Mitchell F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>58c11211ea89f3.11614764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4FDA4FB-352F-40F0-A348-2061C86068F0</gtr:id><gtr:title>The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdcfdb2a611d9920955e1839272fbc81"><gtr:id>cdcfdb2a611d9920955e1839272fbc81</gtr:id><gtr:otherNames>Paterson LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>58bf17b7aa2062.94505120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2B091FA-2B6A-4B4D-9F4A-60E334127EA6</gtr:id><gtr:title>Sex-dependent diversity in ventral tegmental dopaminergic neurons and developmental programing: A molecular, cellular and behavioral analysis.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f53e18a288118fce58f2c276b065876e"><gtr:id>f53e18a288118fce58f2c276b065876e</gtr:id><gtr:otherNames>Gillies GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>doi_55f98598558b82b2</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000018</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>